Intuitive places 468 da Vinci robots as upgrades to da Vinci 5 accelerate, and raises its margin outlook for a second time

Intuitive placed 468 da Vinci surgical systems in the three months to June, 18.5% more than a year earlier, yet its installed base grew by only 315 machines. About 153 older systems therefore left hospital fleets during the quarter through trade-ins, returns or retirements, by MEKAWIRE arithmetic from the company's disclosures, up from about 96 a year before. The Sunnyvale, California company reported the figures with its second quarter 2026 results on 16 July, and they show the upgrade cycle to the da Vinci 5, which made up 246 of the placements, gathering pace.

Revenue rose 19% to $2.89 billion from $2.44 billion, and Intuitive raised its full-year gross margin outlook for the second time this year. Procedure growth, the number its consumables business rests on, is cooling. Da Vinci procedures grew about 15% in the quarter, against about 16% in the first quarter, and the company kept its 2026 forecast at 13.5% to 15.5% while saying it now expects to land closer to the midpoint. How long replacement demand and pay-per-use leasing can keep revenue growing faster than surgical volumes, as Medtronic and others start selling in the United States, is the question these numbers begin to answer.

Instruments still pay the bills, and American hospitals are buying hardware

Instruments and accessories, the tools consumed in each operation, brought in $1.73 billion, up 18%, or about 60% of revenue. Systems revenue reached $685 million against $575 million and services $472.4 million against $391.2 million, the release said. The Form 10-Q filed with the SEC splits the quarter by geography. US revenue rose to $1,933.2 million from $1,629.4 million and revenue outside the United States to $959.1 million from $810.6 million, growth of 18.6% and 18.3% by MEKAWIRE calculation.

The mix beneath those totals differs sharply. US systems revenue climbed 24.9% to $442.1 million, while systems revenue abroad grew 10.1% to $242.9 million. Outside the United States the faster line was consumables, with instruments and accessories up 21.4% to $554.5 million against 16.0% growth in the US, all MEKAWIRE calculations from the 10-Q tables. American hospitals are putting capital into new robots, while hospitals abroad are running more operations on the machines they already have.

Profitability improved faster than sales. Non-GAAP gross margin reached 70.0% against 67.9% a year earlier, and GAAP gross margin 67.8% against 66.3%. GAAP net income attributable to Intuitive was $818 million, or $2.29 per diluted share, compared with $658 million and $1.81. Non-GAAP net income was $1.00 billion, or $2.80 per share, against $0.80 billion and $2.19. The quarter included a benefit of $28 million after tax, or $0.08 per share, from refunds of tariffs paid in earlier periods under the International Emergency Economic Powers Act, the company said. GAAP operating income of $971.9 million equals an operating margin of 33.6% on our arithmetic.

The da Vinci 5 is replacing robots as much as adding them

Da Vinci 5 placements rose 36.7% to 246 from 180, lifting the new model's share of placements to 52.6% from 45.6% a year earlier, slightly below the 53.8% of the first quarter, when it accounted for 232 of 431. The installed base reached 11,710 systems on 30 June, up 12% from 10,488, against 11,395 at the end of March. Subtracting the growth of the base from placements gives the implied number of systems leaving it, 153 in the second quarter, 142 in the first and 96 in the second quarter of 2025. A year ago about one placement in four offset a departing machine. Now it is about one in three. Intuitive does not report trade-ins in its release, so the figure is a ceiling on upgrades rather than a count of them.

Leasing grew faster than outright sales. Intuitive placed 254 systems under operating leases, 54.3% of the total, against 193, or 48.9%, a year earlier, and 131 of those leases were usage-based, so the hospital pays according to how much it operates. The 10-Q shows operating lease revenue of $261.8 million, up from $213.8 million, of which $168.8 million was variable lease revenue against $130.0 million. Under these contracts the robot stays on Intuitive's balance sheet and revenue arrives over the life of the agreement, which smooths income, delays it and ties more of it directly to surgical volumes.

Ion, the company's robotic bronchoscopy platform for lung biopsy, grew procedures by about 36%, down from about 39% in the first quarter. Ion placements were flat at 55 against 54, and its installed base rose 21% to 1,096. Intuitive crossed $10 billion in annual revenue for the first time in 2025, when it placed 1,721 da Vinci systems including 870 da Vinci 5 units, as MEKAWIRE reported in January. First half 2026 revenue of $5.66 billion was 20.7% above the $4.69 billion of the first half of 2025.

The outlook moved on cost, not on volume

Guidance shows where management's confidence has grown. In January Intuitive forecast da Vinci procedure growth of 13% to 15%. It raised that to 13.5% to 15.5% in April, left it unchanged in July and said it expects to finish nearer the midpoint, about 14.5%. The non-GAAP gross margin range has moved up twice, from 67% to 68% in January to 67.5% to 68.5% in April and 68.0% to 69.0% now. The ceiling on operating expense growth has come down from 15% to 14% and then 13%, and the tariff cost built into the outlook fell from 1.2% of revenue to 1.0%. With non-GAAP gross margin at 67.8% in the first quarter and 70.0% in the second, the full-year range leaves room for lower margins in the second half.

Cash, cash equivalents and investments ended June at $8.63 billion, up $0.65 billion in the quarter. Intuitive bought back 0.9 million shares for $0.38 billion, after repurchasing 2.3 million shares for $1.1 billion in the first quarter. Chief executive Dave Rosa said in the release that the results reflected the strength of a portfolio running from da Vinci and Ion to the company's growing digital products.

Rivals are in American operating rooms, but not yet in these numbers

The quarter was the second full one in which Medtronic could sell its Hugo system for urology in the United States, after the FDA cleared it in December 2025 and Cleveland Clinic performed the first US case in February 2026. Johnson & Johnson filed its Ottava robot with the FDA in January, seeking De Novo authorisation. Distalmotion raised $150 million in November 2025 to take its Dexter system into US outpatient surgery centres. In China, MicroPort MedBot more than doubled 2025 revenue to RMB551.1 million with 73% earned overseas, and Edge Medical listed in Hong Kong in January. Intuitive's 18.5% placement growth shows no share loss so far, although the release carries no regional placement data that would reveal it.

The business model explains why the upgrade cycle matters. A da Vinci system is teleoperated, with the surgeon at a console steering instruments mounted on arms at the patient's side, and those instruments and accessories are sold separately and consumed in operations. Every robot in the field feeds that recurring stream plus a service contract. Suppliers feel the cycle too. Japan's Harmonic Drive Systems, which makes precision strain wave gears, reported a large block of surgical robot orders from North America in April to June 2026 without naming the customer.

The risks sit inside the same figures. Da Vinci procedure growth has slowed from about 18% in 2025 to about 16% and then about 15% this year, and the company's midpoint implies a little under 15% for the year. Part of the second quarter margin came from a one-off tariff refund. A larger share of usage-based leases makes revenue more sensitive to hospital volumes, and the release does not say how many of the 153 departing systems were swapped for a da Vinci 5 rather than returned. The July to September report will show whether the replacement pace holds.